In the meta-analysis of clinical trials of patients hospitalized for COVID-19, administration of IL-6 antagonists, compared with placebo or usual care, was associated with lower 28-day all-cause mortality (Shankar-Hari et al., 2021). This evidence concerns the gene IL6 and COVID-19.